Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug
Tweet Send to a Friend
Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
